Table 1.
Characteristic | Number of patients | Median survival time (mo) |
Survival rate (%) |
P-value | |
3-yr | 5-yr | ||||
Overall | 45 | 25 | 51.7 | 36.6 | |
Age (yr) | 0.466 | ||||
≤ 65 | 25 | 42 | 56.4 | 38.7 | |
> 65 | 20 | 33 | 45.5 | 34.1 | |
Gender | 0.314 | ||||
Male | 30 | 35 | 47 | 28.2 | |
Female | 15 | 42 | 58.2 | 48.5 | |
CA19-9 (U/mL) | 0.519 | ||||
≤ 35 | 19 | 42 | 51.6 | 25.8 | |
> 35 | 19 | 55 | 61.5 | 49.2 | |
No data | 7 | ||||
Bilirubin at admission (mg/dL) | 0.368 | ||||
≤ 1.6 | 11 | NR | 53.3 | 53.3 | |
> 1.6 | 34 | 42 | 50.5 | 34.1 | |
Bilirubin at operation (mg/dL) | 0.149 | ||||
≤ 1.6 | 17 | 55 | 65.5 | 43.6 | |
> 1.6 | 28 | 29 | 43.7 | 31.9 | |
Preoperative biliary drainage | 0.632 | ||||
No | 10 | 35 | 40 | 0.0 | |
Yes | 35 | 42 | 53.8 | 42.3 | |
Location | 0.547 | ||||
MBD | 34 | 42 | 51.4 | 44.1 | |
PBD-1 | 11 | 52 | 51.9 | 26 | |
LN dissection | 0.997 | ||||
D1 | 8 | 42 | 58.3 | 29.2 | |
D2 | 37 | 52 | 51.2 | 42.6 | |
Transfusion | 0.832 | ||||
No | 36 | 42 | 51.2 | 39.4 | |
Yes | 9 | 33 | 47.6 | 23.8 | |
Size (cm) | 0.892 | ||||
≤ 2.0 | 26 | 35 | 47 | 39.2 | |
> 2.0 | 19 | 52 | 56.6 | 33.9 | |
T stage | < 0.001 | ||||
T1 | 9 | NR | 100 | 100 | |
T2 | 33 | 35 | 49.6 | 31.5 | |
T3 | 3 | 16 | 0.0 | 0.0 | |
LN stage | 0.010 | ||||
N0 | 32 | 52 | 63.1 | 42.6 | |
N1 | 13 | 25 | 19.2 | 19.2 | |
TNM stage | 0.012 | ||||
Ia | 9 | NR | 100 | 100 | |
Ib | 23 | 42 | 55.8 | 32.6 | |
IIb | 13 | 25 | 19.2 | 19.2 | |
Cell differentiation | 0.005 | ||||
Well | 15 | NR | 87.5 | 57.5 | |
Moderate | 26 | 33 | 41.6 | 33.3 | |
Poor | 4 | 22 | 0.0 | 0.0 | |
Perineural invasion | 0.180 | ||||
No | 13 | NR | 71.1 | 71.1 | |
Yes | 32 | 35 | 47.7 | 29.8 |
BDSR: Bile duct segmental resection; CA19-9: Carbohydrate antigen 19-9; MBD: Middle bile duct cancer; PBD-1: Proximal bile duct cancers; LN: Lymph node; NR: Not reached.